Gene expression and pathway analysis of ovarian cancer cells selected for resistance to cisplatin, paclitaxel, or doxorubicin

Journal of Ovarian Research

Volumn 4, Issue 1, 2011, Pages

  Sherman Baust, Cheryl A ^a   Becker, Kevin G ^a   Wood Iii, William H ^a   Zhang, Yongqing ^a   Morin, Patrice J ^a,b  

^a NATIONAL INSTITUTE ON AGING   (United States)

^b DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DOXORUBICIN; PACLITAXEL;

ARTICLE; CANCER CELL; COMPARATIVE STUDY; GENE EXPRESSION; GENETIC ASSOCIATION; OVARY CANCER; OXIDATIVE STRESS; PHENOTYPE; PRIORITY JOURNAL;

EID: 82655176997     PISSN: None     EISSN: 17572215     Source Type: Journal    
DOI: 10.1186/1757-2215-4-21     Document Type: Article

References (33)

1. Cancer statistics, 2011: The impact of eliminating socioeconomic and racial disparities on premature cancer deaths. Siegel R, Ward E, Brawley O, Jemal A, CA: Cancer J Clin 2011 61 212 236 10.3322/caac.20121
2. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, Clarke-Pearson DL, Davidson M, N Engl J Med 1996 334 1 6 10.1056/NEJM199601043340101 7494563 (Pubitemid 26012496)
3. Combination versus sequential cytotoxic chemotherapy in recurrent ovarian cancer: time for an evidence-based comparison. Markman M, Gynecol Oncol 2010 118 6 7 10.1016/j.ygyno.2010.03.017 20421127
4. Ovarian cancer: strategies for overcoming resistance to chemotherapy. Agarwal R, Kaye SB, Nat Rev Cancer 2003 3 502 516 10.1038/nrc1123 12835670 (Pubitemid 37328838)
5. Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals. Ishida S, Lee J, Thiele DJ, Herskowitz I, Proc Natl Acad Sci USA 2002 99 14298 14302 10.1073/pnas.162491399 12370430 (Pubitemid 35257666)
6. Enhancing tumor-specific uptake of the anticancer drug cisplatin with a copper chelator. Ishida S, McCormick F, Smith-McCune K, Hanahan D, Cancer Cell 2010 17 574 583 10.1016/j.ccr.2010.04.011 20541702
7. Drug discovery approaches targeting the PI3K/Akt pathway in cancer. Garcia-Echeverria C, Sellers WR, Oncogene 2008 27 5511 5526 10.1038/onc.2008.246 18794885
8. Over-expression of PTEN sensitizes human ovarian cancer cells to cisplatin-induced apoptosis in a p53-dependent manner. Yan X, Fraser M, Qiu Q, Tsang BK, Gynecol Oncol 2006 102 348 355 10.1016/j.ygyno.2005.12.033 16545436 (Pubitemid 44063583)
9. Effect of tumor suppressor gene PTEN on the resistance to cisplatin in human ovarian cancer cell lines and related mechanisms. Wu H, Cao Y, Weng D, Xing H, Song X, Zhou J, Xu G, Lu Y, Wang S, Ma D, Cancer letters 2008 271 260 271 10.1016/j.canlet.2008.06.012 18657898
10. PIK3CA amplification associates with resistance to chemotherapy in ovarian cancer patients. Kolasa IK, Rembiszewska A, Felisiak A, Ziolkowska-Seta I, Murawska M, Moes J, Timorek A, Dansonka-Mieszkowska A, Kupryjanczyk J, Cancer Biol & Ther 2009 8 21 26 10.4161/cbt.8.1.7209 22135084
11. Novel strategies for reversing platinum resistance. Shahzad MM, Lopez-Berestein G, Sood AK, Drug Resist Updat 2009 12 148 152 10.1016/j.drup.2009.09.001 19805003
12. Molecular changes in brain aging and Alzheimer's disease are mirrored in experimentally silenced cortical neuron networks. Gleichmann M, Zhang Y, Wood WH, Becker KG, Mughal MR, Pazin MJ, van Praag H, Kobilo T, Zonderman AB, Troncoso JC, et al. Neurobiol Aging 2012 33 205 e201 205 e218
13. Analysis of microarray data using Z score transformation. Cheadle C, Vawter MP, Freed WJ, Becker KG, J Mol Diagn 2003 5 73 81 10.1016/S1525-1578(10) 60455-2 12707371 (Pubitemid 36553428)
14. Claudin-containing exosomes in the peripheral circulation of women with ovarian cancer. Li J, Sherman-Baust CA, Tsai-Turton M, Bristow RE, Roden RB, Morin PJ, BMC Cancer 2009 9 244 10.1186/1471-2407-9-244 19619303
15. Reactome: a database of reactions, pathways and biological processes. Croft D, O'Kelly G, Wu G, Haw R, Gillespie M, Matthews L, Caudy M, Garapati P, Gopinath G, Jassal B, et al. Nucleic Acids Res 2011 39 691 697 10.1093/nar/gkq1018 21067998
16. Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer. Gordon AN, Tonda M, Sun S, Rackoff W, Gynecol Oncol 2004 95 1 8 10.1016/j.ygyno.2004.07.011 15385103 (Pubitemid 39286270)
17. Multidrug resistance in cancer: role of ATP-dependent transporters. Gottesman MM, Fojo T, Bates SE, Nat Rev Cancer 2002 2 48 58 10.1038/nrc706 11902585 (Pubitemid 37328807)
18. Prostate secretory protein (PSP94) suppresses the growth of androgen-independent prostate cancer cell line (PC3) and xenografts by inducing apoptosis. Garde SV, Basrur VS, Li L, Finkelman MA, Krishan A, Wellham L, Ben-Josef E, Haddad M, Taylor JD, Porter AT, et al. The Prostate 1999 38 118 125 10.1002/(SICI)1097-0045(19990201)38:2<118::AID-PROS5>3.0.CO;2-G 9973097 (Pubitemid 29052950)
19. A synthetic 15-mer peptide (PCK3145) derived from prostate secretory protein can reduce tumor growth, experimental skeletal metastases, and malignancy-associated hypercalcemia. Shukeir N, Arakelian A, Chen G, Garde S, Ruiz M, Panchal C, Rabbani SA, Cancer Res 2004 64 5370 5377 10.1158/0008-5472. CAN-04-0788 15289344 (Pubitemid 39006558)
20. Prostate secretory protein of 94 amino acids (PSP-94) and its peptide (PCK3145) as potential therapeutic modalities for prostate cancer. Shukeir N, Garde S, Wu JJ, Panchal C, Rabbani SA, Anti-cancer drugs 2005 16 1045 1051 10.1097/00001813-200511000-00002 16222145 (Pubitemid 41565769)
21. Transfer of chromosome 3 fragments suppresses tumorigenicity of an ovarian cancer cell line monoallelic for chromosome 3p. Cody NA, Ouellet V, Manderson EN, Quinn MC, Filali-Mouhim A, Tellis P, Zietarska M, Provencher DM, Mes-Masson AM, Chevrette M, et al. Oncogene 2007 26 618 632 10.1038/sj.onc. 1209821 16909122 (Pubitemid 46160975)
22. Integrated genomic analyses of ovarian carcinoma. Bell D, Berchuck A, Birrer M, Chien J, Cramer DW, Dao F, Dhir R, Disaia P, Gabra H, Glenn P, et al. Nature 2011 474 609 615 10.1038/nature10166 21720365
23. Targeting multidrug resistance in cancer. Szakacs G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM, Nat Rev Drug Discov 2006 5 219 234 10.1038/nrd1984 16518375 (Pubitemid 43336035)
24. Overexpression of MAGE/GAGE genes in paclitaxel/doxorubicin-resistant human cancer cell lines. Duan Z, Duan Y, Lamendola DE, Yusuf RZ, Naeem R, Penson RT, Seiden MV, Clin Cancer Res 2003 9 2778 2785 12855658 (Pubitemid 36842124)
25. Anoikis mechanisms. Frisch SM, Screaton RA, Curr Opin Cell Biol 2001 13 555 562 10.1016/S0955-0674(00)00251-9 11544023 (Pubitemid 32817013)
26. Remodeling of the Extracellular Matrix Through Overexpression of Collagen VI Contributes to Cisplatin Resistance in Ovarian Cancer Cells. Sherman-Baust CA, Weeraratna AT, Rangel LBA, Pizer ES, Cho KR, Schwartz DR, Shock T, Morin PJ, Cancer Cell 2003 3 377 386 10.1016/S1535-6108(03)00058-8 12726863 (Pubitemid 38340306)
27. Extracellular matrix proteins protect small cell lung cancer cells against apoptosis: a mechanism for small cell lung cancer growth and drug resistance in vivo. Sethi T, Rintoul RC, Moore SM, MacKinnon AC, Salter D, Choo C, Chilvers ER, Dransfield I, Donnelly SC, Strieter R, et al. Nat Med 1999 5 662 668 10.1038/9511 10371505 (Pubitemid 29289430)
28. Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Mitsiades N, Mitsiades CS, Poulaki V, Chauhan D, Fanourakis G, Gu X, Bailey C, Joseph M, Libermann TA, Treon SP, et al. Proc Natl Acad Sci USA 2002 99 14374 14379 10.1073/pnas.202445099 12391322 (Pubitemid 35257679)
29. The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents. Ma MH, Yang HH, Parker K, Manyak S, Friedman JM, Altamirano C, Wu ZQ, Borad MJ, Frantzen M, Roussos E, et al. Clin Cancer Res 2003 9 1136 1144 12631619 (Pubitemid 36323723)
30. Cell cycle-dependent cytotoxicity, G2/M phase arrest, and disruption of p34cdc2/cyclin B1 activity induced by doxorubicin in synchronized P388 cells. Ling YH, el-Naggar AK, Priebe W, Perez-Soler R, Mol Pharmacol 1996 49 832 841 8622633
31. Cyclin D3 activates Caspase 2, connecting cell proliferation with cell death. Mendelsohn AR, Hamer JD, Wang ZB, Brent R, Proc Natl Acad Sci USA 2002 99 6871 6876 10.1073/pnas.072290599 12011445 (Pubitemid 34526225)
32. Degradation of cellular mRNA is a general early apoptosis-induced event. Del Prete MJ, Robles MS, Guao A, Martinez AC, Izquierdo M, Garcia-Sanz JA, FASEB J 2002 16 2003 2005 12397088
33. Triggering and modulation of apoptosis by oxidative stress. Chandra J, Samali A, Orrenius S, Free Radic Biol Med 2000 29 323 333 10.1016/S0891-5849(00) 00302-6 11035261